Page 2 - Melanoma Program News Today

(CNN) — On Friday, the US Food and Drug Administration approved a new, first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin cancer.

On Friday, the US Food and Drug Administration approved a new, first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin cancer.

The Food and Drug Administration approve Amtagvi, a TIL therapy, for patients with advanced melanoma who had disease progression on or after a checkpoint inhibitor and targeted therapy.

(CNN) — On Friday, the US Food and Drug Administration approved a new, first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin<a class="excerpt-read-more" href="https://wsvn.com/news/us-world/fda-approves-new-therapy-for-hard-to-treat-metastatic-melanoma/">Read More</a>

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

The FDA approved Opdivo for the treatment of patients aged 12 years and older with stage 2B or 2C melanoma that has been surgically removed

Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.

Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.

Researchers are making big gains in fighting melanoma.

While the great outdoors offers countless health benefits and lots of fun, it’s important to prioritize sun care.